Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1997;95:1549-1553

This Article
Right arrow Abstract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by De Scheerder, I.
Right arrow Articles by Van de Werf, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Scheerder, I.
Right arrow Articles by Van de Werf, F.

(Circulation. 1997;95:1549-1553.)
© 1997 American Heart Association, Inc.


Articles

Experimental Study of Thrombogenicity and Foreign Body Reaction Induced by Heparin-Coated Coronary Stents

Ivan De Scheerder, MD, PhD; Kai Wang, MD; Krzysztof Wilczek, MD; Dirk Meuleman, PhD; Ronald Van Amsterdam, PhD; Gerard Vogel, BS; Jan Piessens, MD, PhD; Frans Van de Werf, MD, PhD

From the Department of Cardiology (I.D.S., K. Wang, K. Wilczek, J.P., F.V.D.W.), Gasthuisberg, University Hospital, Leuven, Belgium; and Department of Vascular Pharmacology (D.M., R.V.A., G.V.), Organon International BV, Oss, The Netherlands.

Correspondence to I. De Scheerder, MD, PhD, Gasthuisberg University Hospital, Department of Cardiology, Herestraat 49, 3000 Leuven, Belgium.


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Background Results of recent randomized clinical trials have revealed a significant reduction in angiographic restenosis rate when adjunctive stenting was performed after conventional coronary balloon angioplasty. The thrombogenicity of metal stents, however, remains a concern. In the present study, we compare the thrombogenicity of heparin-coated coronary stents with that of bare metallic coronary stents.

Methods and Results Thrombogenicity of metallic coronary stents (four heparin-coated and eight bare stents) was studied in a rat arteriovenous shunt model with the use of 125I-labeled fibrinogen and 51Cr-labeled platelets. Total clot weight after 30-minute follow-up was significantly lower in the heparin-coated stents compared with the bare stents (8.1±3.7 versus 25.8±4.6 mg; P<.001). Relative 125I and 51Cr activities in the stents were significantly higher in the bare stents than in the heparin-coated stents (125I, 1.03±0.43 versus 0.18±0.04, P=.003; 51Cr, 17.5±6.8 versus 4.4±1.0, P=.004). Subsequently, heparin-coated and bare stents were randomly implanted in the right coronary artery of 20 domestic pigs. Angiographic parameters were similar between both groups at baseline and after 6-week follow-up. Morphometry also did not show a significant difference in lumen area (bare, 1.03±0.83 mm2; heparin-coated, 1.12±0.73 mm2; P=NS) or neointimal hyperplasia (bare, 1.01±0.81 mm2; heparin-coated, 1.21±0.57 mm2; P=NS).

Conclusions Heparin coating of metallic coronary stents decreases their thrombogenicity but does not improve late vessel patency and neointimal hyperplasia at follow-up in a porcine coronary model.


Key Words: stents • heparin • thrombus • stenosis


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Metallic coronary stents exert a continuous radial pressure on the diseased coronary artery, resulting in compression of atherosclerotic plaques, sealing of dissections, and expansion of the coronary vessel.1 2 When used as an adjunct to conventional balloon angioplasty, the stents improve vessel patency.3 4

Early clinical experience revealed frequent thrombotic stent closure and abundant healing response, resulting in a more pronounced neointimal hyperplasia compared with conventional balloon angioplasty.2 3 4 5 6 Optimal stent implantation and the use of antiplatelet treatment instead of full anticoagulation significantly decreased thrombotic complications after stent implantation.

Recently, heparin-coated stents were clinically introduced to further decrease in-hospital complications. In the present study, we compare the thrombogenicity of heparin-coated stents with that of bare metallic stents. Furthermore, we evaluate the potential beneficial effect of heparin coating on the increased hyperplastic response to the implanted metallic stent.


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Materials
Self-designed balloon-expandable stainless steel stents were made of 0.18-mm stainless steel wire, folded in a zig-zag shape over a 6F tubular device. These stents can easily be mounted onto any conventional angioplasty balloon and deployed with a minimal pressure of 6 atm.7 8

For the present animal experiments, the stents were coated with Duraflo II heparin (Bentley, Baxter Healthcare Corp).

The Duraflo II coating consists of unfractionated USP heparin and a hydrophobic binding agent. The binding agent is incorporated into the structure of heparin in such a way that the modification affects the physicochemical but not the biological properties of heparin. A submicronic layer of coating was applied to all surfaces of the stent.9 10 11

Stent Thrombogenicity in a Rat Arteriovenous Shunt Model
Heparin-coated (n=4) and bare stainless steel (n=8) stents were deployed in an arteriovenous shunt (internal diameter, 2.0 mm) that was connected between the left carotid artery and the right jugular vein of male Wistar Hsd/Cpb rats (body weight, 300 to 340 g). The thrombogenicity of the stents was considered to be related to the radioactivity measured in the inserted cannula after systemic administration of 125I-labeled fibrinogen and 51Cr-labeled platelets.

After the rats were anesthetized with sodium pentobarbital (60 mg/kg IP), the left carotid artery and the right jugular vein were exposed from the surrounding tissue. The prepared arteriovenous shunt, which was filled with saline, was inserted into the jugular vein and the opposite carotid artery, after which blood circulation via the shunt was started. The segment of the shunt containing the stent was positioned between two detectors that continuously measured the radioactivity of the 51Cr-labeled platelets and 125I-labeled fibrinogen. Blood circulation was monitored by the continuous measurement of the blood flow according to the Doppler flow technique. Blood circulation was allowed for 30 minutes, during which none of the cannulas occluded. Continuous measurements of 51Cr-labeled platelets and 125I-labeled fibrinogen deposition were obtained using the Mumed automated isotope measuring system. At the end of the experiment, the thrombus, removed from the shunt, was characterized by weight and by its 51Cr-labeled platelet and 125I-labeled fibrinogen content. The latter two parameters were measured as the ratio of radioactivity of the clot to the radioactivity of the blood before insertion of the arteriovenous shunt.

Labeling of fibrinogen was performed according to the lactoperoxidase method described by Marchalonis.12 Clottable human fibrinogen (Kabi), 10 to 15 µg per rat, was labeled with 18.5 MBq of I-125 NEZ-033a (E.I. Dupont de Nemours GmBH) and stored in fractions of 150 µL each at -70°C until use to obtain 0.04 to 0.06 MBq for each rat at the day of injection. On the day of the experiment, 1 mL of saline was added to one fraction of 125I-labeled fibrinogen, after which 0.1 mL per rat was injected before insertion of the arteriovenous shunt.

Labeling of platelets was performed according to the method described by Meuleman et al.13 On the day before the experiment, platelets were harvested from donor rats (one donor for two acceptor rats) and labeled with [51Cr]Na2CrO4 (Amersham), 0.9 to 1.7 x 109 platelets, corresponding to 0.4 to 0.8 MBq of 51Cr. Labeling efficiency was 50%. Recovery after 1.5 hours of blood circulation in the rat was 80% to 100%.

Stent Thrombogenicity and Neointimal Response in a Porcine Coronary Model
Stent implantation in the right coronary artery of domestic crossbred pigs was performed according to the method described by De Scheerder et al.14 15

In the first series of experiments, the presence of mural thrombi was studied 7 days after stent implantation. Either a heparin-coated or a bare stent was randomly placed in the right coronary artery of 20 pigs. At 7-day follow-up, quantitative coronary angiography was performed. The pigs were killed with an intravenous bolus of 10 mL of oversaturated potassium chloride. The right coronary artery was harvested for visual inspection of the stent.

In a second series of 20 experiments, the degree of foreign body reaction that occurred at 6 weeks after stent implantation was studied. Either a heparin-coated or a bare stent was randomly deployed in the right coronary artery of 20 pigs. At 6-week follow-up, final angiograms were obtained. The pigs were killed, and the right coronary artery was harvested for histopathology and morphometry. For these late follow-up studies, instrumentation of the pigs and angiographic techniques were identical to those used during the implantation procedure with the exception of intubation with a tracheotomy.

Measurements
Quantitative Coronary Angiography
Angiographic analysis of stented vessel segments was performed before and immediately after stenting and at follow-up with the Polytron 1000 system. The Polytron 1000 system was previously validated in vitro and in vivo16 17 18 with a metal bar as a calibration device.19 The diameter of the stented vessel segments was measured. The degree of oversizing was expressed as the ratio of balloon to artery thickness.

Histopathology and Morphometry
After the 6-week follow-up, the pigs were killed, and the stented coronary segments were carefully dissected together with a 1-cm minimum vessel segment both proximal and distal to the stent. The segment was fixated in a 2% formalin solution. The stent filaments were removed with the use of a stereomicroscope to avoid distortion of or damage to the artery. Sections from each arterial segment were stained with hematoxylin and eosin, van Gieson's elastic, phosphotungstic acid hematoxylin, and Masson's trichrome stains. Light microscopic examination was performed by an experienced pathologist who was blinded to whether coating was applied. Morphometric analysis of the coronary segments harvested was performed with the use of morphometry software (Leitz CBA 8000). Measurements of maximal intimal thickening and of the areas within the lumen (lumen area) and inside the internal elastic lamina (intimal area) were performed on the arterial sites, being visually appreciated as the most proliferative.

Statistical Analysis
Thrombogenicity of the heparin-coated and bare stents was compared with the use of unpaired Student's t tests. Thrombotic events after stent implantation were compared with the use of a {chi}2 test. Arteriographic measurements before, immediately after, and 6 weeks after stent implantation were compared using paired Student's t tests. Comparison of both study groups was performed using unpaired Student's t tests. Data are presented as mean±SD. A value of P<.05 was considered statistically significant.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
Stent Thrombogenicity in the Rat Carotid Arteriovenous Shunt Model
After 30 minutes, the total clot weight in the bare stents was significantly higher than that in the heparin-coated stents. Similarly, many more radioactive 125I-labeled fibrinogen and 51Cr-labeled platelets were measured in the bare stents (Table 1Down and Figs 1Down and 2Down).


View this table:
[in this window]
[in a new window]
 
Table 1. Comparison of Thrombogenicity of Heparin-Coated and Bare Stainless Steel Stents Tested in Rat Arteriovenous Shunt Model



View larger version (24K):
[in this window]
[in a new window]
 
Figure 1. Continuous measurements of 51Cr-labeled platelet deposition on the stented arteriovenous shunt over 30 minutes showing a comparison between the heparin-coated and the control (bare) stents.



View larger version (25K):
[in this window]
[in a new window]
 
Figure 2. Continuous measurements of 125I-labeled fibrinogen deposition on the stented arteriovenous shunt over 30 minutes showing a comparison between the heparin-coated and the control (bare) stents.

Stent Thrombogenicity in Porcine Coronary Arteries
A total of 10 heparin-coated and 10 bare stents were randomly implanted in the right coronary artery of 20 pigs. The angiographic measurements obtained in the stents before, immediately after, and at 7 days after implantation are presented in Table 2Down; no significant differences between stent types were observed. However, after the animals were killed, visual inspection of the stents revealed mural thrombi in 8 bare stents but only 2 heparin-coated stents (P<.02).


View this table:
[in this window]
[in a new window]
 
Table 2. Quantitative Coronary Angiographic Analysis of Stented Vessel Segments at 7-d Follow-up

Foreign Body Reaction Provoked by Stent Implantation in Porcine Coronary Arteries
In a second series of experiments, a total of 10 heparin-coated and 10 bare stents were again randomly implanted in the right coronary artery of 20 pigs. There were no significant differences in the angiographic measurements obtained before, immediately after, and at 6 weeks after stent implantation (Table 3Down). Similarly, the postmortem morphometric analysis showed no difference in the different transversal areas measured at the most reactive intrastent site (Table 4Down). Phosphotungstic acid hematoxylin staining was positive in 9 of the bare metallic stents compared with 2 of the heparin-coated stents (P<.002).


View this table:
[in this window]
[in a new window]
 
Table 3. Quantitative Coronary Angiographic Analysis of Stented Vessel Segments at 6-wk Follow-up


View this table:
[in this window]
[in a new window]
 
Table 4. Morphometry Performed 6 wk After Porcine Right Coronary Artery Stenting


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
The present study shows that metallic stents that are heparin coated result in fewer thrombotic phenomena at the implantation site.

When a heparin-coated stent was implanted in a shunt connecting the carotid artery and jugular vein of Wistar rats, less clot formation was found than after implantation of a bare metallic stent. This observation was reflected in reduced accumulation of radioactive fibrinogen and platelets and a smaller thrombus. Subsequently, when the stents were implanted in normal porcine right coronary arteries, after 7 days, mural thrombi were found in eight bare metallic stents but only two heparin-coated stents (Fig 3Down). These results are concordant with the data recently published by Hårdhammar et al,20 who used another type of heparin coating and demonstrated a significant decrease in subacute thrombotic occlusions in the heparin-coated stents.



View larger version (152K):
[in this window]
[in a new window]
 
Figure 3. Photomicrograph of a stented portion of a vessel. In this case, a bare (noncoated) stent was used. Note the thrombus formation surrounding the stent filament sites (hematoxylin and eosin stain; magnification, x40).

These observations are clinically relevant. Early clinical experience with coronary stents was hampered by early thrombotic stent occlusion resulting in an unacceptable morbidity and even mortality. Optimal stent implantation with intravascular ultrasound and/or high-pressure stent deployment21 and the use of antiplatelet treatment22 23 instead of full anticoagulation significantly decreased this dramatic complication. High-pressure stent deployment, however, can be complicated by distal dissection and increased vessel injury resulting in a more pronounced neointimal hyperplasia,24 and the use of ticlopidine may be limited by systemic hematological side effects. Therefore, heparin-coated stents could represent an attractive alternative, especially in small vessels and more diffuse coronary disease, in which multiple stents or single long stents are needed.

Our longer-term experiments show that after 6 weeks, no difference was present between the intrastent diameters of the heparin-coated and bare stents, as measured either angiographically or morphometrically. This finding may be surprising because earlier experimental studies suggest that platelets, thrombin, and mural thrombosis are involved in the restenosis process.25 26 Fig 3Up shows an example of mural thrombi formation surrounding the stent filaments. Fig 4Down shows an organized mural thrombus at 6-week follow-up, suggesting the important role that organization of mural thrombi might play in the restenosis process. Our results are concordant with the results of Hårdhammar et al.20 They demonstrated a significantly thicker neointima in the heparin-coated stent group compared with the bare stent group after 4-week follow-up. This difference, however, became insignificant after 12-week follow-up. These findings open the debate on the real importance of platelet adhesion and mural thrombi formation on neointimal hyperplasia after stent implantation. After balloon angioplasty, organization of mural thrombi seems to play a major role in the restenosis process. This study suggests, however, that this is less so after stent implantation. Other factors, such as deep injury caused by the deployment of the stent in the diseased artery and a foreign body response caused by the implantation of a foreign body, are potentially more important in the pathogenesis of neointimal hyperplasia after stent implantation.



View larger version (142K):
[in this window]
[in a new window]
 
Figure 4. Photomicrograph of a stented part of the vessel 6 weeks after implantation of a bare (noncoated) stent showing an organized mural thrombus. Phosphotungstic acid hematoxylin staining shows the remaining fibrin in this organized thrombus (magnification, x400).

Conclusions
This study demonstrates that heparin coating of metal coronary stents reduces their thrombogenicity but does not influence the neointimal hyperplasia.


*    Acknowledgments
 
The authors thank Lisa Tam for coating the stents, Tony Stassen for excellent technical assistance, and Joke Tack and An Makowski for excellent secretarial assistance in preparation of the manuscript.

Received July 23, 1996; revision received October 14, 1996; accepted November 4, 1996.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 

  1. Puel J, Juillière Y, Bertrand ME, Rickards AF, Sigwart U, Serruys PW. Early and late assessment of stenosis geometry after coronary arterial stenting. Am J Cardiol. 1988;61:546-553. [Medline] [Order article via Infotrieve]
  2. Serruys PW, Strauss BH, Beatt KJ, Bertrand ME, Puel J, Rickards AF, Meier B, Goy J-J, Vogt P, Kappenberger L, Sigwart U. Angiographic follow-up after placement of a self-expanding coronary artery stent. N Engl J Med. 1991;324:13-17. [Abstract]
  3. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, Goy JJ, van den Heuvel P, Delcan H, Morel M-A, for the BENESTENT Study Group. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331:489-495. [Abstract/Free Full Text]
  4. Fishmann D, Leon M, Baim D, Schatz R, Savage M, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein PS, Fish D, Colombo A, Brinker J, Moses J, Shaknovich A, Hirsfeld J, Bailey S, Ellis S, Rake R, Goldberg S. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331:496-501. [Abstract/Free Full Text]
  5. Bucx JJJ, De Scheerder I, Beatt K, van den Brand M, Suryapranata H, de Feyter PJ, Serruys PW. The importance of adequate anticoagulation to prevent early thrombosis after stenting of stenosed venous bypass grafts. Am Heart J. 1991;121:1389-1396. [Medline] [Order article via Infotrieve]
  6. De Scheerder IK, Strauss BH, de Feyter PJ, Beatt KJ, Baur LHB, Wijns W, Heyndrix GR, Suryapranata H, van de Brand M, Buis B, Serruys PW, Morel MA, Montauban van Swijndrecht E. Stenting of venous bypass grafts: a new treatment modality for patients who are poor candidates for reintervention. Am Heart J. 1992;123:1046-1054. [Medline] [Order article via Infotrieve]
  7. De Scheerder IK, Wang K, Kerdsinchai P, Desmet W, Dens J, Wilczek K, Van Humbeeck J, Piessens JH. Initial clinical experience with a new handmade coronary stent. J Am Coll Cardiol. 1996;27:110A. Abstract.
  8. De Scheerder IK, Wang K, Kerdsinchai P, Verbeken E, Desmet W, Dens J, Wilczek K, Van Humbeeck J, Piessens J. The concept of the home-made coronary stent: experimental results and initial clinical experience. Cathet Cardiovasc Diagn.. 1996;39:191-196. [Medline] [Order article via Infotrieve]
  9. Ito Y, Liu L-S, Matsuo R, Imanishi Y. Synthesis and nonthrombogenicity of polymer membrane with surface-graft polymers carrying thrombin inhibitor. J Biomed Mater Res. 1992;26:1065-1080. [Medline] [Order article via Infotrieve]
  10. Hsu L-C. Duraflo II heparin-immobilized cardiopulmonary bypass: state of the art review. Cardiac Surg. 1993;7:265-276.
  11. Tong S-D, Hsu L-C. Non-thrombogenic hemofiltration system for acute renal failure treatment. ASAIO J. 1992;38:702-706.
  12. Marchalonis M. An enzymic method for the trace iodination of immoglobulin and other proteins. Biochem J. 1969;113:299-305. [Medline] [Order article via Infotrieve]
  13. Meuleman D, Vogel G, Van Delft A. Effects of intra-arterial accumulation on blood platelet consumption in rats. Thromb Res. 1980;20:45-55. [Medline] [Order article via Infotrieve]
  14. De Scheerder IK, Wilczek KL, Verbeken EV, Vandorpe J, Lan PN, Schacht E, De Geest H, Piessens J. Biocompatibility of polymer-coated oversized metallic stents implanted in normal porcine coronary arteries. Atherosclerosis. 1995;114:105-114. [Medline] [Order article via Infotrieve]
  15. De Scheerder IK, Wang K, Wilczek K, Verbeken E, Desmet W, Schacht E, Piessens J. Local methylprednisolone inhibition of foreign body response to coated intracoronary stents. Coron Artery Dis. 1996;7:161-166. [Medline] [Order article via Infotrieve]
  16. Barth K, Eicker B, Bittner U, Marhoff P. The improvement of vessel quantification with image processing equipment for high resolution digital angiography. In: Lemke HV, ed. Computer Assisted Radiology. Berlin, Germany: Springer-Verlag; 1989:220-225.
  17. Galbraith JE, Murphy ML, Desoyza N. Coronary angiogram interpretation: interobserver variability. JAMA. 1981;240:2053-2058.
  18. Fortin DF, Spero LA, Cusma JT, Santoro L, Burgess R, Bashore TM. Pitfalls in the determination of absolute dimensions using angiographic catheters as calibration devices in quantitative angiography. Am J Cardiol. 1991;68:1176. [Medline] [Order article via Infotrieve]
  19. Desmet W, Vrolix M, De Scheerder I, Van Lierde J, De Geest H, Willems JL, Piessens J. Angiotensin-converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty. Circulation. 1994;89:385-392. [Abstract/Free Full Text]
  20. Härdhammar PA, Beusekom HMM, Emanuelsson HU, Hofma SH, Albertson PA, Verdouw PD, Boersma E, Serruys PW. Reduction in thrombotic events with heparin-coated Palmaz-Schatz stents in normal porcine coronary arteries. Circulation. 1996;93:423-430. [Abstract/Free Full Text]
  21. Colombo A, Hall P, Nakamura S, Almagor Y, Maiello L, Martini G, Gagline A, Goldberg SL, Tobis JM. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation. 1995;91:1676-1688. [Abstract/Free Full Text]
  22. Morice MC, Zemour G, Benviste E, Biron Y, Bourdonnec C, Faivre R, Fajadet J, Gaspard P, Glatt B, Joly P, Labrunie P, Lienhart Y, Marco J, Petiteau PY, Royer T, Valeix B. Intracoronary stenting without coumadin: one month results of a French Multicenter Study. Am Heart J. 1995;129:157-164.
  23. Schömig A, Neumann FJ, Kastrati A, Schühlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EA, Richardt G, Alt E, Schmitt K, Ulm K. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents. N Engl J Med. 1996;334:1084-1089. [Abstract/Free Full Text]
  24. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol. 1992;19:267-274. [Abstract]
  25. Ip JH, Fuster V, Israel K, Badimon L, Badimon J, Chesebro JH. The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty. J Am Coll Cardiol. 1991;17:77B-88B.
  26. Gasperetti CM, Gonias SL, Gimple LW, Powers ER. Platelet activation during coronary angioplasty in humans. Circulation. 1993;88:2728-2734.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
Toxicol PatholHome page
M. N. Helmus, D. F. Gibbons, and D. Cebon
Biocompatibility: Meeting a Key Functional Requirement of Next-Generation Medical Devices
Toxicol Pathol, January 1, 2008; 36(1): 70 - 80.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
B. H. Lee, J. E. Lee, K. W. Lee, H. Y. Nam, H. J. Jeon, Y. J. Sung, J. S. Kim, H. J. Lim, J.-s. Park, J. Y. Ko, et al.
Coating with paclitaxel improves graft survival in a porcine model of haemodialysis graft stenosis
Nephrol. Dial. Transplant., October 1, 2007; 22(10): 2800 - 2804.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. Mehran, E. D. Aymong, D. T. Ashby, T. Fischell, H. Whitworth Jr, R. Siegel, W. Thomas, S. C. Wong, R. Narasimaiah, A. J. Lansky, et al.
Safety of an Aspirin-Alone Regimen After Intracoronary Stenting With a Heparin-Coated Stent: Final Results of the HOPE (HEPACOAT and an Antithrombotic Regimen of Aspirin Alone) Study
Circulation, September 2, 2003; 108(9): 1078 - 1083.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. N. Babapulle and M. J. Eisenberg
Coated Stents for the Prevention of Restenosis: Part I
Circulation, November 19, 2002; 106(21): 2734 - 2740.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. Kastrati, H. Schuhlen, and A. Schomig
Stenting for small coronary vessels: a contestable winner
J. Am. Coll. Cardiol., November 15, 2001; 38(6): 1604 - 1607.
[Full Text] [PDF]


Home page
Eur Heart JHome page
P.J. de Feyter
The quest for the ideal stent
Eur. Heart J., October 1, 2001; 22(19): 1766 - 1768.
[PDF]


Home page
Eur Heart JHome page
J Wohrle, E Al-Khayer, U Grotzinger, C Schindler, M Kochs, V Hombach, and M Hoher
Comparison of the heparin coated vs the uncoated Jostent(R)--no influence on restenosis or clinical outcome
Eur. Heart J., October 1, 2001; 22(19): 1808 - 1816.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
D. E. Drachman, E. R. Edelman, P. Seifert, A. R. Groothuis, D. A. Bornstein, K. R. Kamath, M. Palasis, D. Yang, S. H. Nott, and C. Rogers
Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months
J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2325 - 2332.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. H. Baron, A. H. Gershlick, K. Hogrefe, J. Armstrong, C. M. Holt, R. K. Aggarwal, M. Azrin, M. Ezekowitz, and D. P. de Bono
In vitro evaluation of c7E3-Fab (ReoProTM) eluting polymer-coated coronary stents
Cardiovasc Res, June 1, 2000; 46(3): 585 - 594.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Verheye, C. P. Markou, M. Y. Salame, B. Wan, S. B. King III, K. A. Robinson, N. A. F. Chronos, and S. R. Hanson
Reduced Thrombus Formation by Hyaluronic Acid Coating of Endovascular Devices
Arterioscler. Thromb. Vasc. Biol., April 1, 2000; 20(4): 1168 - 1172.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
J Gunn and D Cumberland
Stent coatings and local drug delivery. State of the art
Eur. Heart J., December 1, 1999; 20(23): 1693 - 1700.
[PDF]


Home page
CirculationHome page
E. R. Edelman and C. Rogers
Stent-Versus-Stent Equivalency Trials : Are Some Stents More Equal Than Others?
Circulation, August 31, 1999; 100(9): 896 - 898.
[Full Text] [PDF]


Home page
Circ. Res.Home page
H. M. Nugent, C. Rogers, and E. R. Edelman
Endothelial Implants Inhibit Intimal Hyperplasia After Porcine Angioplasty
Circ. Res., March 5, 1999; 84(4): 384 - 391.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
O. F. Bertrand, R. Sipehia, R. Mongrain, J. Rodes, J.-C. Tardif, L. Bilodeau, G. Cote, and M. G. Bourassa
Biocompatibility aspects of new stent technology
J. Am. Coll. Cardiol., September 1, 1998; 32(3): 562 - 571.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
T. Yamawaki, H. Shimokawa, T. Kozai, K. Miyata, T. Higo, E. Tanaka, K. Egashira, T. Shiraishi, H. Tamai, K. Igaki, et al.
Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo
J. Am. Coll. Cardiol., September 1, 1998; 32(3): 780 - 786.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by De Scheerder, I.
Right arrow Articles by Van de Werf, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Scheerder, I.
Right arrow Articles by Van de Werf, F.